Fig. 4From: Short-term results of early switch from Ranibizumab to Aflibercept in poor or non responder age related macular degeneration in clinical practiceVisual acuity (VA) of the ranibizumab (RBZ) non-responder patients after the 3rd injection of RBZ (mean: 0.53 ± 0.36 logMAR) and after the 3rd injection of aflibercept (AFL) (mean: 0.71 ± 0.44 logMAR)Back to article page